Drug Development and Industrial Pharmacy (DRUG DEV IND PHARM)

Publisher: Informa Healthcare

Journal description

Covering aspects of the development, production, and evaluation of drugs and pharmaceutical products, this international journal highlights both the technical and regulatory facets of industrial pharmacy. Topics addressed within this continually evolving discipline include computerization of production, quality control, export problems, pharmacokinetics and biopharmaceutics, drug regulatory affairs, and successful manufacturing practices.

Current impact factor: 2.10

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 2.101
2013 Impact Factor 2.006
2012 Impact Factor 1.539
2011 Impact Factor 1.494
2010 Impact Factor 1.396
2009 Impact Factor 0.96
2008 Impact Factor 1.104
2007 Impact Factor 1.049
2006 Impact Factor 0.821
2005 Impact Factor 0.787
2004 Impact Factor 0.917
2003 Impact Factor 0.661
2002 Impact Factor 0.57
2001 Impact Factor 0.557
2000 Impact Factor 0.619
1999 Impact Factor 0.497
1998 Impact Factor 0.495
1997 Impact Factor 0.497
1996 Impact Factor 0.529
1995 Impact Factor 0.499
1994 Impact Factor 0.482
1993 Impact Factor 0.42
1992 Impact Factor 0.308

Impact factor over time

Impact factor

Additional details

5-year impact 1.94
Cited half-life 8.10
Immediacy index 0.39
Eigenfactor 0.00
Article influence 0.34
Website Drug Development and Industrial Pharmacy website
Other titles Drug development and industrial pharmacy (Online), Drug development and industrial pharmacy
ISSN 0363-9045
OCLC 39497092
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Informa Healthcare

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • On author's personal website or institution website
    • Publisher copyright and source must be acknowledged
    • Non-commercial
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • NIH funded authors may post articles to PubMed Central for release 12 months after publication
    • Wellcome Trust authors may deposit in Europe PMC after 6 months
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated the applicability of stearic acid as a co-adjuvant in cushioning agent formulated to prevent coat damage when compressing coated pellets. The co-processed and physical blended fillers were prepared by spray drying and physically blending, respectively, with filler ingredients consisting of stearic acid, microcrystalline cellulose, fully gelatinized starch, and corn starch. Pellets containing drug were produced by coating onto non-pariels a drug layer of metformin followed by a sustained-release layer. Drug release from tablets composed of co-processed or physical blended fillers (0, 1, 5, and 10% stearic acid levels) and coated drug containing pellets were analyzed using similarity factor F2. Under the same force and the stearic acid level, co-processed fillers produced pellet containing tablets which showed higher F2 or t50 values and tensile strengths as well as lower yield pressures as compared with tablets containing physical blended fillers. It was shown that the destructive degree of pellet coating was significantly reduced after being co-processed by homogenization and the incorporation of stearic acid in the cushioning agents, as shown by the improved F2 and t50 values. In addition, disintegrate times of tablets containing co-processed agents decreased despite the hydrophobic stearic acid. In conclusion, the inclusion of stearic acid in co-processed cushioning agents was effective at protecting compacted coated pellets from compression-induced damage without compromising disintegratability. The findings could serve as a step towards resolving the technical challenges of balancing the drug release profiles, tablet tensile strength, and disintegration time of compacting coated pellets into multi-particulate-sustained release tablets.
    No preview · Article · Aug 2015 · Drug Development and Industrial Pharmacy
  • [Show abstract] [Hide abstract]
    ABSTRACT: Disintegrants are the key excipients administered in tablet formulations to boost the decomposition of the tablet into smaller pieces in the gastrointestinal environment, thereby increasing the available surface area and enhancing a more rapid release of the active ingredient. Polysuccinimide (PSI), a biodegradable polymer synthesized from aspartic acid, was reacted with starch and fully assessed by CHN, (1)H-NMR, and FTIR. PSI-grafted starch (PSI-St) was synthesized and applied as a disintegrant in the formulation of a rapidly disintegrating tablet of Ondansetron, a nausea and vomiting medicine. The tablet formulated with the newly developed superdisintegrant was evaluated for hardness, friability, disintegration time, and dissolution rate, and the results were compared with tablets formulated with an identical composition of test formulation differing only in type of disintegrant. Tablets prepared with starch and tablets prepared with sodium starch glycolate (SSG) were used as negative and positive controls, respectively. Dissolution study results indicated that although the onset of disintegration action was faster for SSG than PSI-St, higher amounts of drug were released from tablets formulated from PSI-St than from those formulated from SSG during 10 min. It was concluded that the novel synthesized superdisintegrant has an appropriate potential for the application in the formulation of fast dissolving tablets.
    No preview · Article · Aug 2015 · Drug Development and Industrial Pharmacy
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug dispersed in a polymer can improve bioavailability; dispersed amorphous drug undergoes recrystallization. Solid solutions eliminate amorphous regions, but require a measure of the solubility. Use the Flory-Huggins Theory to predict crystalline drugs solubility in the triblock, graft copolymer Soluplus® to provide a solid solution. Physical mixtures of the two drugs with similar melting points but different glass forming ability, sulfamethoxazole and nifedipine, were prepared with Soluplus® using a quick technique. Drug melting point depression (MPD) was measured using differential scanning calorimetry. The Flory-Huggins Theory allowed: (1) interaction parameter, χ, calculation using MPD data to provide a measure of drug-polymer interaction strength and (2) estimation of the free energy of mixing. A phase diagram was constructed with the MPD data and glass transition temperature (Tg) curves. The interaction parameters with Soluplus® and the free energy of mixing were estimated. Drug solubility was calculated by the intersection of solubility equations and that of MPD and Tg curves in the phase diagram. Negative interaction parameters indicated strong drug-polymer interactions. The phase diagram and solubility equations provided comparable solubility estimates for each drug in Soluplus®. Results using the onset of melting rather than the end of melting support the use of the onset of melting. The Flory-Huggins Theory indicates that Soluplus® interacts effectively with each drug, making solid solution formation feasible. The predicted solubility of the drugs in Soluplus® compared favorably across the methods and supports the use of the onset of melting.
    No preview · Article · Aug 2015 · Drug Development and Industrial Pharmacy
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: It is well known that microemulsions are mainly utilized for their transdermal rather than their dermal drug delivery potential due to their low viscosity, and the presence of penetration enhancing surfactants and co-surfactants. Objective: Applying quality by design (QbD) principles, a tazarotene microemulsion formulation for local skin delivery was optimized by creating a control space. Materials and methods: Critical formulation factors (CFF) were oil, surfactant/co-surfactant (SAA/CoS), and water percentages. Critical quality attributes (CQA) were globular size, microemulsion viscosity, tazarotene skin deposition, permeation, and local accumulation efficiency index. Results and discussion: Increasing oil percentage increased globular size, while the opposite occurred regarding SAA/CoS, (p = 0.001). Microemulsion viscosity was reduced by increasing oil and water percentages (p < 0.05), due to the inherent high viscosity of the utilized SAA/CoS. Drug deposition in the skin was reduced by increasing SAA/CoS due to the increased hydrophilicity and viscosity of the system, but increased by increasing water due to hydration effect (p = 0.009). Models with very good fit were generated, predicting the effect of CFF on globular size, microemulsion viscosity, and drug deposition. A combination of 40% oil and 45% SAA/CoS showed the maximum drug deposition of 75.1%. Clinical skin irritation study showed that the aforementioned formula was safe for topical use. Conclusion: This article suggests that applying QbD tools such as experimental design is an efficient tool for drug product design.
    No preview · Article · Jul 2015 · Drug Development and Industrial Pharmacy
  • [Show abstract] [Hide abstract]
    ABSTRACT: In Vitro In Vivo Correlation ship; with 5 main building blocks: 1. ASSUMED IVIVC: Establishment of theoretical in vitro targets by solubility & permeability study in multimedia on Drug Substance itself. 2. RETROSPECTIVE IVIVC: Establishment of practical in vitro targets by comparing in vitro % drug dissolved on at least 6 units with in vivo % drug absorbed on prototype formulation of Drug Product on at least 6 subjects at pilot scale with defined IVIVR. 3. PROSPECTIVE IVIVC: Formulation Optimization by challenging critical formulation variables by predicting in vivo plasma drug concentration from in vitro % drug absorbed by using already defined IVIVR. 4. SCALE UP: Process Optimization of final Manufacturing Process by challenging CPPs at pilot scale & scaling up the process during exhibit/submission batch with extensive in vitro multimedia dissolution profiling on 12 units & in vivo pharmaco-kinetic profiling on at least 12 subjects. 5. DOSSIER FILING FOR PRODUCT REGISTRATION: After regulatory approval, any minor variation in formulation/ process can be waived on the basis of SUPAC guideline justified by developed validated IVIVC Model
    No preview · Article · Jun 2015 · Drug Development and Industrial Pharmacy
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, aqueous diltiazem HCl and polyvinyl-pyrrolidone (PVP) solutions were mixed with Kollicoat SR 30D and spray dried to microparticles of different drug:excipient ratio and PVP content. Co-spray dried products and physical mixtures of drug, Kollidon SR and PVP were tableted. Spray drying process, co-spray dried products and compressibility/compactability of co-spray dried and physical mixtures, as well as drug release and water uptake of matrix-tablets was evaluated. Simple power equation fitted drug release and water uptake (R2>0.909 and 0.938, respectively) and correlations between them were examined. Co-spray dried products with PVP content lower than in physical mixtures result in slower release, while at equal PVP content (19 and 29% w/w of excipient) in similar release (f2>50). Increase of PVP content increases release rate and co-spray drying might be an alternative, when physical mixing is inadequate. Co-spray dried products show better compressibility/compactability but higher stickiness to the die-wall compared to physical mixtures. SEM observations and comparison of release and swelling showed that distribution of tableted component affects only the swelling, while PVP content for both co-spray dried and physical mixes is major reason for release alterations and an aid for drug release control.
    No preview · Article · Jun 2015 · Drug Development and Industrial Pharmacy

  • No preview · Article · Jan 2015 · Drug Development and Industrial Pharmacy
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim to design an effective breviscapine nanoscale drug delivery system to realize the improvement of its oral bioavailability. Based on the investigations of the stabilities in the gastrointestinal tract (GIT), permeation and efflux across the cell membrane, the breviscapine nanoemulsion (NE) was formulated and evaluated in vitro and in vivo. The globule size and polydispersity index of the NE was 45.6 nm and 0.105, and the efficient encapsulation was 95.2%. In vitro, the drug release from NEs in pH 6.8 PBS fit to the first-order kinetics. The Caco-2 cell transport experiments showed that the breviscapine NE facilitated the improvement of the apparent permeability coefficient (Papp) from the apical side to basilar side compared with the free drug. In vivo, the relative bioavailability of breviscapine NE reached to 249.7%. All the studies implicated that the NE carrier contributed to the enhancement of the oral absorption of breviscapine due to the improved stability and permeation in the GIT. The nanoemulsions technology is better for the poor permeable and unstable active agents in GIT as well as helps the industrial scale process.
    No preview · Article · Aug 2014 · Drug Development and Industrial Pharmacy